The main objective of this observational survey is to estimate the incidence, the typology, and the evolution of patients with acute myelobalstic leukemia, aged more than 60 years old. In this age group (aged more than 60y), three groups of patients with very different response rates and late outcome can be delineated with specific standard chemotherapy.
Study Type
OBSERVATIONAL
Enrollment
1,000
Avicenne
Bobigny, Île-de-France Region, France
RECRUITINGcumulative incidence of failures
failures include * resistant disease defined according to the IWG AML response criteria * hypoplastic marrow after D42 and absence of myeloidrecovery * early relapse up to 9 months from CR : Either AML relapse as in the IWG classification or MDS relapse
Time frame: 9 months
response rate
Time frame: 9 months
relapse rate
Either AML relapse as in the IWG classification \- Or MDS relapse defined for this study as follows: (i) Persistent cytopenias, if unexplained by other cause, and (ii) myelodysplastic marrow with less than 20% marrow blasts in two samples taken 3 months apart
Time frame: within 2 years after inclusion
overall survival
Time frame: within 2 years after inclusion
adverse events
Time frame: within 2 years after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.